Cannabis might help pediatric IBD symptoms but evidence is far too limited to recommend use

While cannabis shows potential anti-inflammatory effects relevant to inflammatory bowel disease, the evidence in pediatric IBD is insufficient to support clinical use, with calls for more targeted research on safety and efficacy in children.

Halbmeijer, Nienke et al.·Expert review of clinical pharmacology·2019·Preliminary EvidenceReview
RTHC-02059ReviewPreliminary Evidence2019RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Review
Evidence
Preliminary Evidence
Sample
Not reported

What This Study Found

Cannabis may relieve IBD symptoms and improve quality of life in individual patients. The endocannabinoid system plays a role in gastrointestinal tract function with potential anti-inflammatory effects. However, no adequate pediatric evidence exists to recommend cannabis or cannabinoids for IBD in children.

Key Numbers

Rising incidence of pediatric IBD onset. Current treatment relies on immunomodulatory therapy. Cannabis and purified ingredients show potential anti-inflammatory effects. No adequate pediatric safety or efficacy data exist.

How They Did This

Narrative review of recent literature on cannabis use in IBD with a focus on pediatric patients, including background on the endocannabinoid system in the gastrointestinal tract and discussion of various cannabis forms and purified ingredients.

Why This Research Matters

Pediatric IBD is rising, and parents are increasingly asking about cannabis options. This review provides clinicians with a framework for discussing why cannabis cannot yet be recommended for children with IBD despite adult-oriented enthusiasm.

The Bigger Picture

The gap between adult interest in cannabis for IBD and pediatric evidence is particularly stark. Children metabolize drugs differently, have developing immune systems, and face different risk-benefit calculations than adults, making extrapolation from adult data inappropriate.

What This Study Doesn't Tell Us

Narrative review without systematic methodology. Limited primary research on cannabis in pediatric IBD. Draws mostly from adult data and extrapolation. Does not quantify the strength of anti-inflammatory effects.

Questions This Raises

  • ?What specific cannabinoids might be safest and most effective for pediatric IBD?
  • ?Could topical or rectal administration minimize systemic exposure in children?
  • ?What outcomes should pediatric clinical trials prioritize?

Trust & Context

Key Stat:
Pediatric IBD is rising, but cannabis cannot yet be recommended for children
Evidence Grade:
Preliminary: narrative review acknowledging a fundamental lack of pediatric-specific evidence.
Study Age:
Published in 2019.
Original Title:
Cannabis, a potential treatment option in pediatric IBD? Still a long way to go.
Published In:
Expert review of clinical pharmacology, 12(4), 355-361 (2019)
Database ID:
RTHC-02059

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study

Summarizes existing research on a topic.

What do these levels mean? →

Frequently Asked Questions

Can cannabis help children with IBD?

It might, based on anti-inflammatory mechanisms and some adult patient reports. However, there is not enough evidence to recommend cannabis for pediatric IBD. The authors call for targeted pediatric research before any clinical use.

Why can't we just use adult IBD data for children?

Children metabolize drugs differently, have developing immune systems, and face different risks. Extrapolating adult cannabis data to children is inappropriate without pediatric-specific studies on safety and efficacy.

Read More on RethinkTHC

Cite This Study

RTHC-02059·https://rethinkthc.com/research/RTHC-02059

APA

Halbmeijer, Nienke; Groeneweg, Michael; De Ridder, Lissy. (2019). Cannabis, a potential treatment option in pediatric IBD? Still a long way to go.. Expert review of clinical pharmacology, 12(4), 355-361. https://doi.org/10.1080/17512433.2019.1582330

MLA

Halbmeijer, Nienke, et al. "Cannabis, a potential treatment option in pediatric IBD? Still a long way to go.." Expert review of clinical pharmacology, 2019. https://doi.org/10.1080/17512433.2019.1582330

RethinkTHC

RethinkTHC Research Database. "Cannabis, a potential treatment option in pediatric IBD? Sti..." RTHC-02059. Retrieved from https://rethinkthc.com/research/halbmeijer-2019-cannabis-a-potential-treatment

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.